What is Genfit?
Founded in 1999 and headquartered in Loos Hauts-de-France, Genfit operates within the competitive bio-pharmaceutical landscape. The company is dedicated to developing innovative therapeutic and diagnostic solutions aimed at addressing unmet needs in the critical areas of metabolic and inflammatory diseases. Its strategic focus on these complex health conditions positions it as a key player in the search for novel treatments and diagnostic tools.
How much funding has Genfit raised?
Genfit has raised a total of $703M across 13 funding rounds:
Share Placement
$15.5M
Share Placement
$5.4M
Share Placement
$22.7M
Share Placement
$36.6M
Share Placement
$48.2M
Debt
$194.5M
Stock Offering
$155.4M
Debt
$13.3M
Debt
$200M
Share Placement (2013): $15.5M, investors not publicly disclosed
Share Placement (2014): $5.4M, investors not publicly disclosed
Share Placement (2014): $22.7M, investors not publicly disclosed
Share Placement (2016): $36.6M, investors not publicly disclosed
Share Placement (2016): $48.2M, investors not publicly disclosed
Debt (2017): $194.5M, investors not publicly disclosed
Stock Issuance/Offering (2019): $155.4M, investors not publicly disclosed
Debt (2021): $13.3M led by The French Government
Debt (2025): $200M supported by HealthCare Royalty Management
Key Investors in Genfit
HealthCare Royalty Management
HealthCare Royalty Management is a specialized investment organization focused on providing capital solutions to companies within the biopharmaceutical sector, often through royalty interests and tailored financing arrangements.
The French Government
The French Government has provided debt financing, indicating support for strategic national industries or companies with significant economic or health impact.
OSEO
OSEO, a French innovation agency, has supported Genfit through various financing rounds, highlighting its role in fostering technological advancement and growth in French companies.
What's next for Genfit?
The substantial enterprise-level funding and recent strategic investment indicate Genfit is likely in a growth or scaling phase, potentially preparing for late-stage clinical trials, market expansion, or further research and development initiatives. The company's commitment to advancing its pipeline suggests a forward-looking strategy focused on bringing impactful solutions to patients suffering from metabolic and inflammatory disorders. Future developments will likely center on clinical trial progress, regulatory approvals, and commercialization efforts.
See full Genfit company page
